Peptoid blocking O-GlcNAcylated NF-kappaB c-Rel
US12398185B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2020 |
| Grant date | Aug 26, 2025 |
| Priority date | — |
| Expiry date | Dec 24, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to peptoids for inhibiting O-GlcNAcylated proteins, and in particular, the c-Rel peptide of NF-kappaB. The compounds can be used in the prevention or treatment of diseases of conditions having elevated levels of O-GlcNAcylation, such as autoimmune diseases, conditions that are related to hyperglycemia, or cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.